Last reviewed · How we verify
lipid-lowering drug(Statin)
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels in the blood.
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels in the blood. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of risk of myocardial infarction and stroke.
At a glance
| Generic name | lipid-lowering drug(Statin) |
|---|---|
| Sponsor | First Affiliated Hospital of Wenzhou Medical University |
| Drug class | HMG-CoA reductase inhibitor (Statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Statins competitively bind to HMG-CoA reductase and block the conversion of HMG-CoA to mevalonate, a critical early step in the cholesterol biosynthetic pathway. This leads to decreased hepatic cholesterol production, upregulation of LDL receptors on liver cells, and enhanced clearance of LDL cholesterol from circulation. Statins also have pleiotropic anti-inflammatory and endothelial-protective effects beyond cholesterol lowering.
Approved indications
- Hypercholesterolemia and dyslipidemia
- Primary and secondary prevention of cardiovascular disease
- Reduction of risk of myocardial infarction and stroke
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes (transaminitis)
- Rhabdomyolysis (rare)
- Headache
- Gastrointestinal upset
Key clinical trials
- Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients
- Optimizing Non-statin Agents for ASCVD
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial (PHASE2)
- Combined Effects of Statins and Exercise on Training Sensitive Health Markers (NA)
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Community-based, eHealth Supported Type 2 Diabetes Care by Lay Village Health Workers in Rural Lesotho (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: